- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02376933
Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer
Phase 2 Study of Vertebral Augmentation and Radiotherapy in Painful or at Risk of Collapse Spinal Metastatic Cancer/Multiple Myeloma
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85724
- University of Arizona
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of metastatic disease to the vertebra or multiple myeloma
- Negative pregnancy test within 2 weeks prior to registration
- Life expectancy of >= 3 months and Karnofsky performance status (KPS) score >= 40
- Pain scale score >=5
- Pain at involved vertebral body not adequately controlled
- Osteolysis of vertebral bodies
- Must agree to practice adequate means of birth control
- Must sign informed consent prior to study entry
- Must be able to understand the English language
- Absence of any serious cognitive or psychiatric problems potentially hampering compliance with the study and follow-up schedule.
Exclusion Criteria:
- Spinal Cord Compression
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Vertebroplasty with Radiotherapy
Vertebroplasty with Radiotherapy is given in either order.
Radiotherapy dosage is at the discretion of the treating physician.
Vertebroplasty is applied to fractured vertebrae.
|
Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
Andre navne:
Radiotherapy of metastatic lesions to the spine.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Assessment From the Worst Pain Score on Brief Pain Inventory as Compared to Historical Radiation Therapy Oncology Group (RTOG) 9714 Study.
Tidsramme: 14 weeks
|
Assessment of the patient's pain, activities and quality of life will be gathered from the patient in returning for follow-up or by contacting the patient by phone approximately 1 week following the completion of their first procedure, whether it be the vertebral augmentation or the radiotherapy (5 - 10 days following). Mandatory assessments include: - Worst Pain Score - Brief Pain Inventory (BPI) - The Worst Pain Assessment on the Brief Inventory Scale is an assessment tool of current pain intensity and pain intensity within the last 24 hours when not on pain control medications. 0 being no pain and 10 is the worst pain possible. See protocol attachments |
14 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Activity Level Assessment From the Roland Morris Questionnaire (RDQ) and Karnofsky Performance Status (KPS)
Tidsramme: 14 weeks
|
Roland-Morris Disability Questionnaire - The score of the RDQ is the total number of items checked - i.e. from a minimum of 0 (best) to a maximum of 24 (worst). Karnofsky Performance Status (KPS) - scale from 10 (moribund, fatal processes progressing rapidly) to 100 (normal, no complaints, no evidence of disease). |
14 weeks
|
|
Quality of Life Assessment From the EORTC QLQ C30 Questionnaire.
Tidsramme: 14 weeks
|
EORTC QLQ-C30 (version 3) - The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning,a high score for the global health status / QoL represents a high QoL,but a high score for a symptom scale / item represents a high level of symptomatology / problems. |
14 weeks
|
|
Fracture Rates Detected From X-rays.
Tidsramme: 14 weeks
|
14 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Krisha Howell, MD, University of Arizona Radiation Oncology
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Brud, Knogle
- Sår og skader
- Hæmatologiske sygdomme
- Hæmoragiske lidelser
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Neoplastiske processer
- Rygmarvsskader
- Rygskader
- Neoplasmer
- Myelomatose
- Neoplasmer, Plasmacelle
- Neoplasma Metastase
- Spinalfrakturer
- Neoplasmer, Anden Primær
Andre undersøgelses-id-numre
- 1300000562
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Myelomatose
-
Guangzhou Bio-gene Technology Co., LtdTrukket tilbageMultiple myeloma -ildfast
-
Zhongshan Hospital (Xiamen), Fudan UniversityIkke rekrutterer endnuMyelomprogression | Multiple myeloma -ildfast
-
University Health Network, TorontoRekrutteringMyelom i tilbagefald | Multiple myeloma -ildfastCanada
-
Baskent UniversityIkke rekrutterer endnuMULTIPL SKLEROSETyrkiet (Türkiye)
-
Minsk Scientific-Practical Center for Surgery,...RekrutteringAnti-BCMA CAR-T-celleterapi for voksne med tilbagevendende eller refraktær myelomatose (MSTH-CAR001)Multiple myeloma -ildfastHviderusland
-
HuniLife Biotechnology, Inc.Tilmelding efter invitationMultiple myeloma -ildfastTaiwan
-
Hebei Senlang Biotechnology Inc., Ltd.Peking University People's Hospital; Institute of Hematology & Blood Diseases...Ikke rekrutterer endnuMyelom i tilbagefald | Multiple myeloma -ildfast
-
CellCentric Ltd.RekrutteringMyelom i tilbagefald | Multiple myeloma -ildfastForenede Stater, Det Forenede Kongerige
-
PETHEMA FoundationRekrutteringDe novo multiple myeloma | Anitocabtagene AutoleucelSpanien
-
CHU de Quebec-Universite LavalRekrutteringRecidiverende myelomatose | Multiple myeloma -ildfastCanada
Kliniske forsøg med Vertebroplasty
-
Centre Hospitalier Universitaire de NīmesTrukket tilbageBrud på hvirvelkropskompression
-
Szeged UniversityAfsluttetVertebral kompressionsbrudUngarn
-
UNC Lineberger Comprehensive Cancer CenterMedtronicRekrutteringThoracale neoplasmer | Lumbal neoplasiForenede Stater
-
National and Kapodistrian University of AthensRekrutteringRadiofrekvensablation | Rygsøjlens metastaser | Vertebral metastase | Knoglekræft MetastatiskGrækenland
-
TeknimedRekrutteringVertebral fraktur | Osteoporotiske frakturer | KompressionsbrudSpanien, Frankrig, Ukraine, Portugal
-
AO Foundation, AO SpineRekrutteringOsteoporose | Osteoporotiske frakturerDet Forenede Kongerige, Finland, Forenede Stater, Argentina, Brasilien, Chile, Egypten, Tyskland, Indien, Japan, Malaysia, Rumænien, Saudi Arabien, Schweiz
-
Ohio State University Comprehensive Cancer CenterRekrutteringHæmatopoietisk og lymfoid celle-neoplasma | Ondartet fast neoplasma | Metastatisk malign neoplasma i rygsøjlenForenede Stater